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Abstract
The gabapentinoid drugs gabapentin and pregabalin are key front-line therapies
for various neuropathies of peripheral and central origin. Originally designed as
analogs of GABA, the gabapentinoids bind to the a2d-1 and a2d-2 auxiliary
subunits of calcium channels, though only the former has been implicated in
the development of neuropathy in animal models. Transgenic approaches also
identify a2d-1 as key in mediating the analgesic effects of gabapentinoids, how-
ever the precise molecular mechanisms remain unclear. Here we review the cur-
rent understanding of the pathophysiological role of the a2d-1 subunit, the
mechanisms of analgesic action of gabapentinoid drugs and implications for
efficacy in the clinic. Despite widespread use, the number needed to treat for
gabapentin and pregabalin averages from 3 to 8 across neuropathies. The failure
to treat large numbers of patients adequately necessitates a novel approach to
treatment selection. Stratifying patients by sensory profiles may imply common
underlying mechanisms, and a greater understanding of these mechanisms
could lead to more direct targeting of gabapentinoids.
Abbreviations
GBPs, gabapentinoids; DRG, dorsal root ganglia; NA, noradrenaline; GABA, c-ami-
nobutyric acid; PAG, periaqueductal gray; Ce, central nucleus of the amygdala; H,
hypothalamus; LC, locus coeruleus; IC, insula cortex; ACC, anterior cingulate cor-
tex; RVM, rostral ventromedial medulla; VGCC, voltage gated calcium channel;
SNL, spinal nerve ligation.
Introduction
The anticonvulsant gabapentin was first reported as pro-
viding pain relief 20 years ago (Mellick et al. 1995). The
discovery that anticonvulsants could be used as analgesics
started a scientific journey leading to the inclusion of
gabapentinoids as key frontline therapy for various neu-
ropathies. However, as with drugs of other classes, the
NNT (number needed to treat) for gabapentinoids vary
considerably between disease states (Finnerup et al. 2015).
One of the perennial clinical questions is why do some
patients respond positively to a treatment whereas others
do not? Undoubtedly animal models have contributed
immensely to our understanding of the neurobiology of
pain. This is particularly evident with gabapentin where
the back translation highlighted the permissive conditions
for analgesic activity and the mechanisms that underpin
these. Prior to the establishment of nerve injury models,
drugs were commonly characterized using the rat paw
formalin test, and Carrageenan-induced mechanical
hyperalgesia and thermal hyperalgesia since it was thought
that enhanced pain processing was the key factor to
understanding pain mechanisms without consideration of
the very different peripheral drivers of pain from nerve
and tissue damage. In addition, measures of thermal
hyperalgesia and tactile allodynia in the rat postoperative
pain model were employed. Although gabapentin shows
efficacy in some of these models (Shimoyama et al. 1997;
Stanfa et al. 1997), we now know that the effects of nerve
injury and inflammation are very different and that these
short-term inflammatory events are not indicative of per-
sistent inflammation such as arthritis for which models
now exist. Rather, now and at the time, the non-nerve
injury models induced peripheral and central changes in
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pain processing that were thought to underlie the more
persistent pains, independent of the causes. A key paper
was Hunter et al. in 1997. The Hunter study was a land-
mark but very tellingly, the title is “The effect of novel
anti-epileptic drugs in rat experimental models of acute
and chronic pain.” So even here, the concept was not that
nerve injury necessarily would be different from other
models but was of longer duration than the acute tests
and that acute tests may not be predictive of persistent
pain. They further state, “this ability to acutely reverse a
prominent manifestation of neuronal sensitization
demonstrates the potential of these drugs as analgesics for
the relief of chronic pain following tissue or nerve injury.
Moreover, the negligible effect of these drugs against an
acute, high threshold thermal noxious stimulus suggests a
selective interaction with pathways associated with patho-
physiological events rather than with normal sensory
nociceptive function.” Herein we review the current
understanding of the state-dependent mechanisms of the
gabapentinoids, the pathophysiological role of their
molecular target, the a2d calcium channel subunit, and
the implications for clinical usage.
a2d Auxiliary Calcium Channel
Subunits
Originally designed as analogs of GABA (Fig. 1), neither
gabapentin nor pregabalin has any significant agonist-like
effect on GABAA or GABAB receptors, nor obvious effects
on levels of GABA (Lanneau et al. 2001; Jensen et al.
2002). Gabapentin was discovered to bind to a2d subunits
(Fig. 2) (Gee et al. 1996), with greater affinity for a2d-1
(Kd = 59 nmol/L) compared to a2d-2 (Kd = 153 nmol/L)
and no affinity for a2d-3 (Marais et al. 2001). The main
biophysical and pharmacological properties of voltage
gated calcium channels (VGCCs) are determined by the
pore-forming a1 subunit, whereas the a2d, b and c com-
ponents influence trafficking and activation kinetics
(Arikkath and Campbell 2003). In vitro, a2d subunits
indiscriminately associate with a1 subunits of VGCCs; the
tissue selective expression of calcium channel components
determine the composition and biophysical properties of
heteromeric complexes in vivo (Dolphin 2013). In gen-
eral, in heterologous expression systems, a2d subunits
increase maximum current density and accelerate activa-
tion and inactivation of calcium currents (De Waard and
Campbell 1995; Klugbauer et al. 1999; Hobom et al.
2000). The increase in current density is dependent on
a2d subunits-enhancing trafficking of a1 to the cell mem-
brane rather than directly influencing channel kinetics
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Figure 1. Structure of GABA, gabapentin and pregabalin.
Figure 2. Topology of a2d subunits. All subunits are products of a
single-gene cleaved posttranslation and joined by disulphide bridges
(De Jongh et al. 1990). The d subunit is anchored to the plasma
membrane through a glycosylphosphatidylinositol anchor (Davies
et al. 2010). Putative N-glycosylation sites have been identified on
both domains. The approximate position of the von Willebrand factor
A domain (required for trafficking of a1 subunit of VGCCs (Canti
et al. 2005)) is shown in close proximity to gabapentin and
pregabalin-binding site in a2d-1 and a2d-2 (RRR).
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(Felix et al. 1997). a2d-1 may also stabilise calcium
channels at the cell surface as its absence promotes inter-
nalization and degradation of channel complexes (Bern-
stein and Jones 2007), though this finding was not
replicated in neuronal cultures (Cassidy et al. 2014).
Within the spinal cord, a2d-1 is predominantly expressed
presynaptically in the dorsal horn localized to the superfi-
cial laminae with moderate expression postsynaptically on
deeper neurones (Li et al. 2006; Bauer et al. 2009). The
presynaptic expression is highest in a subset of small diame-
ter DRG neurones, predominantly C-fibres, with moderate
levels in a minor proportion of large diameter neurones
(Taylor and Garrido 2008). a2d subunits are critical in traf-
ficking of calcium channels to active zones of synapses, and
controlling calcium influx and subsequent transmitter
release (Hoppa et al. 2012). Within areas of the brain asso-
ciated with nociceptive processing, moderate to strong
expression has also been observed in the dorsal raphe, peri-
aqueductal gray, locus coeruleus, and amygdala (Cole et al.
2005; Taylor and Garrido 2008). In the cerebellum, a2d-2
subunits are concentrated within lipid raft microdomains
(Davies et al. 2006). Lipid raft association has not been
confirmed within the dorsal horn or in primary afferent
fibres where a2d-1 has been shown to be anterogradely
transported following nerve ligation (Bauer et al. 2009),
but the localization of a2d to lipid rafts could have conse-
quences for nociceptive transduction as depletion of choles-
terol enhances peak calcium currents (Davies et al. 2006).
Role of a2d-1 in Normal Sensory
Function and Experimental
Neuropathy
a2d-1 knockout mice were originally characterized as
exhibiting reduced myocardial contractibility and
decreased peak L-type calcium current amplitude in car-
diac myocytes (Fuller-Bicer et al. 2009). Contrasting
reports exist regarding whether a2d-1 is required for mus-
cle development (Gach et al. 2008; Garcia et al. 2008),
however no obvious muscle weakness is apparent in the
knockout mice (Fuller-Bicer et al. 2009; Patel et al. 2013).
Distension of the bladder occurs in a minor proportion of
a2d-1 knockout mice (Fuller-Bicer et al. 2009), consistent
with a role of the a2d-1 subunit in the contractibility of
smooth muscle cells (Bannister et al. 2009). Subsequent
studies examined somatosensory functions; a2d-1 knock-
out mice were shown to exhibit behavioral deficits in
mechanical and cold sensitivity, but not heat sensitivity, a
feature that corresponded with wide dynamic range
(WDR) neuronal responses to the same stimuli (Patel et al.
2013). This likely relates to a reduction in trafficking of N-
type calcium channels to presynaptic terminals of primary
sensory afferents in the dorsal horn (Patel et al. 2013).
After nerve injury, transcriptional alterations that occur
are considered to be an adaptive response to preserve
neuronal function. These changes can contribute to neu-
ronal hyperexcitability and spinal plasticity in neuropathic
pain. Numerous studies have identified an up-regulation
of a2d-1 in DRG neurones (Luo et al. 2001; Costigan
et al. 2002; Wang et al. 2002; Xiao et al. 2002) and the
spinal cord (Boroujerdi et al. 2008; Bauer et al. 2009)
after nerve injury, though supraspinal changes have not
been examined in neuropathic models. Spinal nerve liga-
tion (SNL) induces increased levels of a2d-1 in presynap-
tic terminals of primary afferent fibres in the dorsal horn
in addition to an accumulation proximal to the ligation
indicative of anterograde trafficking (Bauer et al. 2009).
Elevated DRG expression of a2d-1 is readily detectable
after SNL peaking 7 days after injury and declining after
several months, a feature that temporally correlates with
the emergence and cessation of neuropathic like evoked
behaviors (Luo et al. 2001). A circadian fluctuation in
DRG a2d-1 expression also correlates with changes in
behavioral hypersensitivity during light and dark phases
(Kusunose et al. 2010). Established mechanical hypersen-
sitivity can be reversed by intrathecal antisense oligonu-
cleotides and prevented by dorsal rhizotomy at the time
of nerve ligation (Li et al. 2004). a2d-1 knockout mice,
however, exhibit a delay in developing mechanical hyper-
sensitivity following nerve injury. In the early parts of the
model, a2d-1 expression appears to be a rate-limiting fac-
tor in transmitting abnormal peripheral activity to central
neurones and is key in shaping the initiation of neuro-
pathic pain, but the absence of a2d-1 fails to prevent
chronicity and is not essential in the maintenance of a
neuropathic state (Patel et al. 2013).
Some of the mechanisms by which increased a2d-1
expression facilitates excitatory transmission in neuro-
pathic animals have been examined in transgenic mice
overexpressing a2d-1. In the absence of injury, these
transgenic mice have mechanical withdrawal thresholds
comparable to nerve ligated wildtype controls (Li et al.
2006), and this may in part be dependent on increased
a2d-1 mediated trafficking of L- and N-type calcium
channels to the dorsal horn (Chang et al. 2015). DRG
neurones from transgenic mice exhibit a hyperpolarizing
shift in the voltage activation of VGCCs, increased peak
conductance and an increased inactivation (Li et al.
2006). Deep dorsal horn WDR neurones in transgenic
mice exhibit responses to low threshold mechanical and
heat stimulation of the receptive field greater than high
threshold stimuli in wild-type mice. A pronounced and
prolonged after-firing characteristic of central neuronal
hyperexcitability is also notable (Li et al. 2006), though
electrically evoked wind-up is unaltered in transgenic
mice suggesting no change in intrinsic WDR excitability
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(Li et al. 2006; Nguyen et al. 2009). Overexpression of
a2d-1 increases the frequency, but not the amplitude, of
mEPSCs in the dorsal horn and is reversed by gabapentin,
and inhibition of AMPA and NMDA receptors (Nguyen
et al. 2009; Zhou and Luo 2014). These data support an
increase in afferent excitability and subsequent spinal neu-
ronal responses in mediating behavioral abnormalities in
a2d-1 overexpressing mice. Interestingly, the increase in
mechanical withdrawal thresholds observed in a2d-1
overexpressing mice following intrathecal ondansetron (a
5-HT3R antagonist) bears marked similarities to the
inhibitory effect of ondansetron on mechanically evoked
neuronal responses in SNL rats suggesting overexpression
of a2d-1 in the absence of injury is sufficient to drive
changes in descending serotonergic facilitations which ter-
minate on these spinally expressed receptors (Suzuki et al.
2004; Chang et al. 2013).
Mechanisms of Gabapentinoid
Activity after Neuropathic Injury
The mechanism of action of gabapentinoids at the cellular
level and after neuropathy has been the subject of much
debate. Can a single molecular mechanism explain all
aspects of analgesia? Point mutation of arginine 217 in
a2d-1 or genetic ablation of a2d-1 completely abolishes
the antinociceptive effects of pregabalin in neuropathic
mice (Field et al. 2006; Patel et al. 2013). Several mecha-
nisms of gabapentin have been proposed after neuropathy
including an inhibition of NMDA receptors, inhibition of
sodium currents and reducing b4a subunit mediated
VGCC trafficking (Hara and Sata 2007; Mich and Horne
2008; Yang et al. 2009). Nevertheless, molecular and
transgenic studies strongly support a2d-1 as the sole
molecular target for the analgesic actions of gabapenti-
noid drugs (summarized in Fig. 3).
Numerous studies confirm that gabapentinoids do not
perturb normal detection and pain thresholds (Attal et al.
1998; Dirks et al. 2002); the pathophysiological state-
dependent effects of pregabalin and gabapentin implies
other factors influence efficacy in neuropathic conditions.
a2d subunits have been implicated in mediating excitatory
synapse formation through astrocyte-derived throm-
bospondins independent from their role with calcium
channels and is a process that is sensitive to gabapentin
inhibition (Eroglu et al. 2009). It is unclear as to whether
the analgesic effect of gabapentinoids is in part dependent
on inhibiting new synapse formation, however this seems
somewhat unlikely given that these agents are efficacious
long after the development of neuropathy when presum-
ably synaptic sprouting has already occurred.
Gabapentin and pregabalin are thought to inhibit
transmitter release, though the precise molecular mecha-
nism is currently undefined. The most plausible explana-
tion would be a direct inhibition of VGCCs, yet calcium
currents are not consistently reduced by acute gabapentin
(Stefani et al. 1998; Sutton et al. 2002; Hendrich et al.
2008), whereas chronically applied gabapentin can reduce
P-type and N-type calcium currents (Hendrich et al.
2008). Similarly in cultured tissue slices, gabapentin does
not consistently inhibit transmitter release (Fink et al.
2000; Fehrenbacher et al. 2003; Brown and Randall 2005;
Quintero et al. 2011). These findings are perhaps unsur-
prising given they were performed in normal tissue and
the analgesic effects of gabapentinoids are mainly revealed
by neuropathy. After up-regulation in DRG neurones, the
a2d-1 subunit can influence activity-dependent calcium
signaling that could affect signaling cascades related to
aberrant neurotransmission (D’Arco et al. 2015). An
additional hypothesis proposed is that gabapentinoids
could reduce neuronal hyperexcitability by modulation of
these pathways.
Chronic systemic pregabalin treatment in SNL rats
inhibits trafficking of a2d-1 to presynaptic terminals in
the dorsal horn (Bauer et al. 2009). Whether this mecha-
nism would account for the acute effects of pregabalin in
models of neuropathy seems unlikely given the time scale
of axonal trafficking (Hunter et al. 1997; Field et al. 2006;
Miyazaki and Yamamoto 2012; Patel et al. 2013). At the
cell surface gabapentin does not disrupt the interaction
between a2d-1 and a1B subunits (Cassidy et al. 2014).
Gabapentin also fails to inhibit the internalization rate of
a2d-2 but does disrupt rab11-dependent recycling from
endosomal compartments consequently reducing calcium
currents through this mechanism (Tran-Van-Minh and
Dolphin 2010). It is tempting to speculate that at the
spinal level, acute pregabalin and gabapentin treatment
preferentially targets channel cycling pathways (Fig. 4),
the rate of which may be influenced by multiple conver-
gent factors governing pre-synaptic excitability after neu-
ropathy. One candidate is PKC, as the up-regulation has
been implicated in the development of neuropathy (Hua
et al. 1999) and gabapentin inhibits transmitter release
only after PKC-dependent phosphorylation within spinal
circuits (Maneuf and McKnight 2001; Fehrenbacher et al.
2003).
In neuropathy, permissible conditions for the inhibi-
tory actions of spinally delivered gabapentinoids also
depend on interactions between a2d-1 and descending
brainstem facilitations terminating on spinal 5-HT3Rs.
Targeted saporin conjugate disruption of a spino-bulbal-
spinal loop comprising spinal NK1+ projection neurones,
or l-opioid receptor-expressing neurones in the rostral
ventromedial medulla (RVM) negates gabapentin and
pregabalin mediated inhibition of spinal neuronal
excitability in neuropathic rats (Suzuki et al. 2005; Bee
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and Dickenson 2008). Remarkably, in na€ıve rats, mimick-
ing increased facilitatory drive by applying a 5-HT3R ago-
nist spinally now induces a state permissible for the
inhibitory actions of pregabalin (Suzuki et al. 2005). The
depolarizing effect of activating pre-synaptic 5-HT3Rs
could consequently alter the kinetics and/or cycling of
calcium channels and create the required conditions for
gabapentin to inhibit calcium currents and transmitter
Figure 3. Sites of action of gabapentinoid drugs. Nerve injury induces synaptic plasticity, central sensitization, increased descending serotonergic
facilitation and reduced descending noradrenergic inhibition of spinal neuronal excitability. Gabapentinoid drugs have been demonstrated to
inhibit trafficking of the a2d-1 subunit from DRG neurones to central terminals in the dorsal horn. Spinally administered gabapentinoids in
neuropathic rats reduce dorsal horn neuronal responses to peripheral stimuli. This effect is highly influenced by an increase in descending
serotonergic facilitations. Gabapentinoids have also been proposed to restore deficiencies of descending noradrenergic inhibition, although the
spinal effects do not depend on this pathway. Gabapentinoids reduce elevated spontaneous and evoked activity in the amygdala, though this
may occur secondary to reduced spinal neuronal activity. (GBPs, gabapentinoids; DRG, dorsal root ganglia; NA, noradrenaline; PAG,
periaqueductal gray; Ce, central nucleus of the amygdala; H, hypothalamus; LC, locus coeruleus; IC, insula cortex; ACC, anterior cingulate cortex;
RVM, rostral ventromedial medulla).
ª 2016 The Authors. Pharmacology Research & Perspectives published by John Wiley & Sons Ltd,
British Pharmacological Society and American Society for Pharmacology and Experimental Therapeutics.
2016 | Vol. 4 | Iss. 2 | e00205
Page 5
R. Patel & A. H. Dickenson Gabapentinoids and Chronic Pain
release (Suzuki et al. 2005). In contrast the conditions for
the inhibitory effects of pregabalin in visceral hyperalgesia
are independent of l-opioid receptor-positive neurones of
the RVM (Sikandar et al. 2012), and reflects differential
brainstem control of cutanueous and visceral stimulation
(Sikandar and Dickenson 2011).
Central sensitization and the subsequent engagement of
descending influences, in some cases in the absence of
pathology, is a key determinant of gabapentinoid analge-
sia and is evident in both humans and preclinical models.
Neither gabapentin nor pregabalin inhibit acute nocicep-
tive reflex responses in uninjured rodents (Field et al.
1997). In contrast, both drugs frequently display inhibi-
tory activity in models with features of central sensitiza-
tion such as after nerve ligation, but also in models where
neuropathy is not the only component such as
osteoarthritis and cancer-induced bone pain or com-
pletely absent such as with opioid-induced hyperalgesia
(Donovan-Rodriguez et al. 2005; Suzuki et al. 2005;
Bannister et al. 2011; Thakur et al. 2012). In the case of
opioid-induced hyperalgesia, pregabalin suppresses spinal
neuronal hyperexcitability in the absence of both pathol-
ogy and up-regulation of a2d-1 (Bannister et al. 2011).
Here, as after neuropathy, negating the effects of descend-
ing facilitation results in the loss of pregabalin efficacy,
supporting that increased descending facilitation sustains
spinal neuronal hyperexcitability in opioid-induced
hyperalgesia and that this mechanism underpins the state-
dependent inhibitory actions of pregabalin (Bannister
et al. 2011). In healthy human volunteers, topically
applied capsaicin is the archetypal model of central sensi-
tization characterized by ongoing afferent activity leading
to primary and secondary hyperalgesia and increased
descending facilitatory drive (O’Neill et al. 2012). Both
acute and chronic gabapentin are analgesic in capsaicin-
induced hyperalgesia and can reduce areas of secondary
hyperalgesia (Gottrup et al. 2004; Iannetti et al. 2005).
Brainstem activity detected by functional MRI is consis-
tent with increased descending facilitatory drive in this
model (Iannetti et al. 2005). A link between these
Figure 4. Cellular mechanisms of gabapentinoid drugs in the dorsal horn. a2d-1 and b subunits of VGCCs mediate forward trafficking of
channels from the endoplasmic reticulum, and this process can be facilitated by PKC. Descending facilitations activating presynaptic ionotropic 5-
HT3Rs results in membrane depolarization and may have consequences for VGCC activity. Gabapentinoids inhibit rab11-dependent recycling of
endosomal VGCCs while having no effect on the interaction between a2d-1 and VGCCs at the membrane. An inhibition of channel recycling
results in reduced channel expression at the synaptic membrane and a decrease in transmitter release. Independent of its association with VGCCs,
a2d-1 can interact with extracellular matrix proteins such as thrombospondins and mediate excitatory synaptogenesis, a process that is also
inhibited by gabapentin. (GBPs, gabapentinoids; PKC, protein kinase C; VGCCs, voltage-gated calcium channels).
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descending facilitations and the actions of the gabapenti-
noids could be the targeting of TRPV1 (so pain transmit-
ting) central terminals by 5-HT3 facilitations (Kim et al.
2014); this sensitization could permit the actions of the
drugs through a2d-1 actions on non-neuropathic pains
without up-regulation of the subunit.
Both intrathecally and intracerebroventricularly deliv-
ered gabapentin are efficacious after peripheral nerve
injury (Tanabe et al. 2005; Hayashida et al. 2007; Takeu-
chi et al. 2007), the effect of the latter in part hypothe-
sized to result from a disinhibition of locus coeruleus
neurones promoting release of noradrenaline in the dorsal
horn and is reversible by intrathecal a2 receptor antago-
nists (Tanabe et al. 2005; Takasu et al. 2008). Systemic
pregabalin has also been shown to normalise elevated
spontaneous and evoked neuronal activity in the central
nucleus of the amygdala (Ce) in neuropathic states (Gon-
calves and Dickenson 2012). This effect may occur
directly within the Ce or secondary to a reduction in
spinal neuronal activity and in turn influence inhibitory
and facilitatory output through the periaqueductal gray,
locus coeruleus and RVM. Anxiolytic-like activity of pre-
gabalin is dependent on a2d-1 but not a2d-2 (Lotarski
et al. 2011), and elevated expression of a2d-1 in the
amygdala correlates with increased predator odour-
induced anxiety and can be reversed by pregabalin (Nasca
et al. 2013). Pregabalin displays an anxiolytic effect in
patients (Feltner et al. 2003), and is now licenced for gen-
eralized anxiety disorders, and could indirectly influence
pain perception through ascending or descending path-
ways.
Implications for Clinical Efficacy
Going forward, it is important to consider the factors
that may predict gabapentinoid efficacy and how to tailor
treatment for individual patients. From this account, it is
clear that a number of neurobiological events in pain
contribute to the permissive neuronal milieu needed for
actions of the drugs on the a2d-1 subunits. In practice, it
would be difficult to infer underlying mechanisms from
symptoms in a patient and therefore drug efficacy, but
there is an ever-increasing body of evidence that sub-
grouping patients may be beneficial to predicting drug
efficacy and this approach could be considered when pre-
scribing gabapentinoids. Insights from animal studies
identify up-regulation of the a2d-1 subunit as a key factor
for gabapentinoid analgesia (Luo et al. 2001; Bauer et al.
2009). Interestingly, a2d-1 splice variants exert similar
effects on calcium currents, however after spinal nerve
ligation variants are differentially expressed, in particular
a variant with lower affinity for gabapentin and it is pos-
sible in some patients that expressional differences
account for some of the variation in efficacy observed
clinically (Lana et al. 2014). Single doses of gabapenti-
noids can alleviate ongoing pain and evoked pain (Berry
and Petersen 2005), on much shorter times scales than
required for axonal trafficking; clearly mechanisms inde-
pendent of inhibiting trafficking are also important and
here we have discussed the descending controls in this
context.
A number of clinical trials suggest peri-operative
gabapentinoids provide a small reduction in postoperative
pain and opioid consumption (Schmidt et al. 2013).
Meta-analysis of studies evaluating the effect of peri-
operative gabapentinoids have been complicated by com-
paring differing surgical procedures with varying propen-
sity to developing chronic pain and further limited by
low statistical power, variations in dosing regimes and a
lack of long-term follow up studies (>6 months). These
longer follow up studies do not consistently demonstrate
reduced incidences of neuropathic pain. Drawing parallels
with the delayed development of neuropathy in a2d-1
knockout mice, treatment at the time of injury might not
necessarily prevent chronicity. In contrast, in established
neuropathy, meta-analysis supports that gabapentin and
pregabalin display efficacy in various neuropathies of
peripheral and central origin (Moore et al. 2009, 2014;
Wiffen et al. 2013). The largest of these studies have been
performed in postherpetic neuralgia and diabetic neu-
ropathy, as well as fibromyalgia, which is not a neuro-
pathic state. This efficacy in patients with nerve injury
has lead to the proposal that osteoarthritis patients with
neuropathic features would also be likely to benefit from
gabapentinoid therapy (Thakur et al. 2014). Here preclin-
ical studies reveal an action of the drugs in osteoarthritis
models where there are neuropathic components and an
up-regulation of a2d-1 levels in ipsilateral L3 and L4
DRG as well as induction of descending facilitations but
not in “pure” osteoarthritis where these changes are
absent (Rahman et al. 2009; Thakur et al. 2012). Though
to date, only one clinical trial has demonstrated the
potential benefit of combination therapy in osteoarthritis
with pregabalin and meloxicam (Ohtori et al. 2013).
Ongoing pain scores are typically used as primary end-
points of efficacy in clinical trials complicating direct
comparisons with animal studies where evoked stimuli
are most often used, but in neuropathic rats gabapentin
produces conditioned place preference, an indicator of
reward and relief from ongoing pain (Griggs et al. 2015),
and reduces spontaneous spinal neuronal activity, a possi-
ble neuronal correlate of ongoing pain (Suzuki and Dick-
enson 2006). Secondary outcome measures such as sleep
and anxiety have shown improvement in some trials
(Dworkin et al. 2003; van Seventer et al. 2010; Kim et al.
2011). Reports of negative trials involving gabapentin and
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pregabalin have also emerged and could be caused by the
heterogeneity of patient groups rather than ineffectiveness
of the drugs per se (Simpson et al. 2010; Kim et al. 2011).
Post hoc analysis of baseline patient data from these trials
supports that no sensory profile is associated with a par-
ticular etiology and identifies distinct transetiological clus-
ters (Freeman et al. 2014). Overall pregabalin was not
superior to placebo treatment in a trial involving HIV
neuropathy patients; retrospective analysis however
revealed pregabalin was more effective in subgroups
exhibiting pinprick hyperalgesia (Simpson et al. 2010).
Similarly in human experimental models of pain, gaba-
pentin and pregabalin are effective against secondary pin-
prick hyperalgesia (Werner et al. 2001; Dirks et al. 2002;
Segerdahl 2006; Chizh et al. 2007) and are particularly
effective on mechanical responses of spinal cord neurones
in animals. Although there are conflicting reports regard-
ing the efficacy of gabapentinoids in inflammatory and
neuropathic models against mechanical and thermal
hypersensitivity, in neuropathic animals at least, these
agents preferentially inhibit spinal neuronal responses to
punctate and dynamic mechanical stimulation compared
to thermal stimulation (Donovan-Rodriguez et al. 2005;
Bee and Dickenson 2008; Thakur et al. 2012). This is also
supported by some clinical observations that heat pain
thresholds are not frequently increased by gabapentinoids
whereas mechanical pain thresholds are (Attal et al. 1998;
Werner et al. 2001). Gabapentinoids can be efficacious
against allodynia, hyperalgesia and ongoing pain in facili-
tated states independent of etiology. Variations in efficacy
could also be shaped by activity within descending modu-
latory pathways and these circuits may be directly modu-
lated by gabapentinoids.
Conditioned pain modulation (CPM) in healthy vol-
unteers and patients provides a readout of the efficiency
of descending inhibitory output, and has been utilized as
a predictive tool for drug efficacy. Both human and ani-
mal studies demonstrate that CPM or diffuse noxious
inhibitory controls (DNIC) are reduced or absent in
neuropathic conditions, that reducing the effect of
descending facilitation or enhancing inhibitions reveal
DNIC in neuropathic rats, and low CPM predicts effi-
cacy of duloxetine (SNRI) and tapentadol (MOR-NRI)
in diabetic neuropathy patients (Yarnitsky et al. 2012;
Niesters et al. 2014; Bannister et al. 2015). Thus it could
be expected that low CPM would be predictive of effi-
cacy of any drugs that restore imbalances between
descending inhibitory and excitatory influences. Although
gabapentinoids have been suggested to act supraspinally
in the locus coeruleus (Tanabe et al. 2005; Takasu et al.
2008), the only human study to date demonstrates low
CPM does not predict pregabalin efficacy in pancreatitis
patients with widespread cutaneous sensitization (Olesen
et al. 2013), inconsistent with a role in enhancing
descending noradrenergic inhibitory drive. Functional
MRI analysis reveals gabapentin reduces brainstem acti-
vation induced by cutaneous capsaicin sensitization (Ian-
netti et al. 2005), but this could occur secondary to its
spinally mediated effects rather than direct actions within
the brainstem. Further studies are required to examine
the correlation between gabapentinoids and CPM in
other conditions but temporal summation also warrants
further investigation. Temporal summation is frequently
enhanced in neuropathic conditions and is seen as a
proxy for central sensitization. Drugs shown to reduce
central sensitization also inhibit temporal summation
including ketamine and gabapentin (Koppert et al. 2001;
Arendt-Nielsen et al. 2007).
Conclusion
Numerous lines of pre-clinical and clinical evidence sup-
port that gabapentinoids can be useful treatments in con-
ditions where features of central sensitisation are present,
in particular secondary pinprick hyperalgesia. Animal stu-
dies unequivocally demonstrate that the a2d-1 calcium
subunit controls transmitter release and up-regulation
further facilitates excitatory transmission in neuropathic
conditions, and that the interaction of gabapentinoids
with a2d-1 is necessary for the analgesic actions. At the
cellular and molecular level, multiple mechanisms could
account for the acute and chronic effects of dosing in
neuropathic patients. Adverse effects associated with
gabapentinoids, including somnolence, dizziness and
ataxia, occur in healthy volunteers implying an ability to
modulate transmitter release within the CNS. Further-
more, de novo sensitivity of those with chronic pain, epi-
lepsy and anxiety disorders to gabapentinoids implicates
other factors within CNS circuits that determine the
additional inhibitory activity of these drugs. The com-
parative effects of gabapentinoids in animal models and
neuropathic patients are suggestive of similar processes
being involved. It is worth considering continuation of
profiling and sub-grouping of patients within trials as
this could lead to the identification of better predictors
of efficacy.
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